Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib PK study with Rabeprazole and Coca-Cola
NCT04489797Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Primary completion
- Aug 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to infinity, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration and 1 more. Started Jul 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04489797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04489797.